10 Apr 2026 Study: Most bispecific antibodies lack postapproval improvements to overall survival, quality of life Many of the bispecific antibodies (BsAbs) approved by global regulators have yet to demonstrate robust clinical benefit beyond surrogate endpoints that led to their initial approval, according to research published in BioDrugs. Regulatory News